# Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage

Study · id `cardio:ct-nct06673602` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06673602](<https://clinicaltrials.gov/study/NCT06673602>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06673602

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06673602. Randomized; no masking; primary purpose treatment. Start 2024-11-04 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06673602, source copy `cardio:ctgov-nct06673602-2024-11-06`, retrieved 2026-10-31)
- Started: 2024-11-04 (actual) (ClinicalTrials.gov record NCT06673602, source copy `cardio:ctgov-nct06673602-2024-11-06`, retrieved 2026-10-31)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06673602, source copy `cardio:ctgov-nct06673602-2024-11-06`, retrieved 2026-10-31)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06673602, source copy `cardio:ctgov-nct06673602-2024-11-06`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06673602, source copy `cardio:ctgov-nct06673602-2024-11-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06673602-2024-11-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
- Condition: Cognitive Impairment
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): FCYC+Conventional treatment
- Intervention (Drug): conventional treatment
- Lead sponsor: Qinhuangdao Hospital of Traditional Chinese Medicine
- Lead sponsor class: OTHER
- Collaborator: Kaifeng Third People's Hospital
- Collaborator class: UNKNOWN
- Collaborator: Second Affiliated Hospital of Tsinghua University
- Collaborator class: OTHER
- Collaborator: Weifang Hospital of Traditional Chinese Medicine
- Collaborator class: OTHER
- Collaborator: Shandong Public Health Clinical Center
- Collaborator class: OTHER\_GOV
- Collaborator: Kunming Sanbo Brain Hospital
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)

## Provenance

Content hash: 91f9549926e323b2a7bcd7cd3dea3b6eed1a8ba44450c147f789cb602e2737dc
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
